P.C | Jotup

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Innodata, Fox Factory, Lantronix, and Palo Alto Networks and Encourages Investors to Contact the Firm

Retrieved on:

Monday, March 18, 2024

Innodata also stopped disclosing its Research and Development spend after the first quarter of 2021.

Key Points:

Innodata also stopped disclosing its Research and Development spend after the first quarter of 2021.
On this news, the price of Innodata common stock declined by $3.74 per share, or approximately 30.5%, on February 15, 2024.
The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nextdoor, and Snowflake and Encourages Investors to Contact the Firm

Retrieved on:

Monday, March 18, 2024

Growth, Shareholder, COVID-19, Internet, Snowflake Inc., News, Acquisition, IPO, Networking hardware, SNOW, ARPU, P.C, Video game

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points:

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
On this news, the price of Nextdoor Class A common stock fell approximately 11%, further damaging investors.
which lowered credit consumption.” On this news, the price of Snowflake Class A common stock fell nearly 28% over several trading sessions, damaging investors.
For more information on the Snowflake class action go to: https://bespc.com/cases/SNOW

FUTURE FINTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Future FinTech Group Inc. and Encourages Investors to Contact the Firm

Retrieved on:

Sunday, March 17, 2024

Fintech, Telephone, District court, Security (finance), P.C, Defendant, Court, Person

NEW YORK, March 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Future FinTech Group Inc. (“Future FinTech” or the “Company”) (NASDAQ: FTFT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Future FinTech securities between March 10, 2020 and January 11, 2024, both dates inclusive (the “Class Period”).

Key Points:

NEW YORK, March 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Future FinTech Group Inc. (“Future FinTech” or the “Company”) (NASDAQ: FTFT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Future FinTech securities between March 10, 2020 and January 11, 2024, both dates inclusive (the “Class Period”).
Investors have until March 18, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
There is no cost or obligation to you.

ALLOVIR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against AlloVir, Inc. and Encourages Investors to Contact the Firm

Retrieved on:

Sunday, March 17, 2024

Clinical research associate, Telephone, District court, News, P.C, Court, Person, Pharmaceutical industry

Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
Specifically, AlloVir said it was discontinuing the posoleucel Phase 3 studies after pre-planned analyses concluded they wouldn’t meet their primary endpoints.
On this news, AlloVir’s stock price fell $1.57 per share, or 67.38%, to close at $0.76 per share on December 22, 2023.

BIOVIE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioVie Inc. and Encourages Investors to Contact the Firm

Retrieved on:

Sunday, March 17, 2024

GCP, Risk, Telephone, District court, COVID-19, Patient, Good clinical practice, P.C, Clinical trial, OSI, FDA, Court, Food, Person, Pharmaceutical industry

Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
On November 29, 2023, BioVie, Inc. issued a press release accompanying an investor presentation disclosing top line data from its clinical trial of NE3107 for the treatment of mild to moderate Alzheimer’s Disease.
Upon trial completion, the Company found significant deviation from protocol and Good Clinical Practice (GCP) violations at 15 sites.

HIRERIGHT ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of HRT and Encourages Investors to Contact the Firm

Retrieved on:

Saturday, March 16, 2024

HRT, Sponsor, Telephone, Acquisition, General Atlantic, P.C, Squire, Learning, HireRight

On February 16, 2024, HireRight announced that it had entered into an agreement to be acquired by the Sponsors in a $1.65 billion all-cash deal.

Key Points:

On February 16, 2024, HireRight announced that it had entered into an agreement to be acquired by the Sponsors in a $1.65 billion all-cash deal.
Pursuant to the merger agreement, the Sponsors will acquire all of the outstanding shares they do not already own for $14.35 per share in cash.
Bragar Eagel & Squire is concerned that HireRight’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for HireRight’s stockholders.

EMBARK ALERT: Bragar Eagel & Squire, P.C. is Investigating Embark Technology, Inc. f/k/a Northern Genesis Acquisition Corp. II on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on:

Saturday, March 16, 2024

Our investigation concerns whether the board of directors of Embark have breached their fiduciary duties to the company.

Key Points:

Our investigation concerns whether the board of directors of Embark have breached their fiduciary duties to the company.
Headquartered in San Francisco, California, Embark is a Delaware corporation that builds software for carriers to enable autonomous trucks within their fleets.
The autonomous vehicle company offers software as a service product ecosystem, such as Embark driver, Embark universal interface, and Embark guardian.
Legacy Embark was a startup company that developed self-driving truck technology designed for freight and logistic services.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on:

Saturday, March 16, 2024

Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points:

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
As of the time this Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

ANAVEX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the Firm

Retrieved on:

Friday, March 15, 2024

Telephone, District court, Patient, News, Rett syndrome, P.C, Clinical trial, MCI, Radar, Court, Person

Investors have until May 13, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until May 13, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
Biotech analysts commented that “the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results.”
Following this news, AVXL’s stock price fell by $3.26 per share, or approximately 35%.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on:

Friday, March 15, 2024

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points:

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.